Drug Profile
NE 11040
Latest Information Update: 06 Aug 1998
Price :
$50
*
At a glance
- Originator Procter & Gamble
- Class Cardiac glycosides; Heart failure therapies
- Mechanism of Action Adenosine triphosphatase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Heart failure
Most Recent Events
- 06 Aug 1998 No-Development-Reported for Heart failure in USA (Unknown route)
- 09 Oct 1995 New profile
- 09 Oct 1995 Preclinical development for Heart failure in USA (Unknown route)